Accu check meter

Fasting blood glucose levels were measured at 0, 2, 4, and 8 weeks after febuxostat treatment using an Accu-check meter (Roche Diagnostics, St. Louis, MO, USA). After scarifying, blood HbA1c was measured using a DCA Vantage Analyzer (Siemens Healthineers, Erlangen, Germany) and serum cystatin C level was assessed with a mouse cystatin C enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems, Minneapolis, MN, USA). The serum creatinine, urine creatinine, and serum uric acid levels were checked using an IDEXX VetTest^® Chemistry Analyzer (IDEXX Laboratories, Inc., Westbrook, ME, USA). Urinary albumin excretion was assessed via ACR on spot urine collection. Urine albumin levels were quantified using a Mouse Albumin ELISA Quantification Set (Bethyl Laboratories, Montgomery, TX, USA), following the manufacturer’s protocols.

All blood samples were obtained after overnight fasting. The fasting blood glucose was measured by an Accu-check meter (Roche Diagnostics, St Louis, Mo, USA). The HbA1c was determined from red cell lysates by HPLC (Bio-Rad, Richmond, CA, USA). Total cholesterol, TG and FFA concentrations were measured by an auto-analyzer (Wako, Osaka, Japan).

After 12 weeks of resveratrol treatment, blood glucose was measured using an Accu-check meter (Roche Diagnostics, St. Louis, MO, USA). Hemoglobin A1c (HbA1c) was determined from red cell lysates by HPLC (Bio-Rad, Richmond, CA, USA). The concentration of serum adiponectin was determined by ELISA (Biosource, Camarillo, CA, USA). Total cholesterol and triacylglycerol (TG) concentrations were measured with an autoanalyzer (Hitachi 917, Tokyo, Japan) using commercial kits (Wako, Osaka, Japan). Nonesterified fatty acid (NEFA) levels were measured with a JCA-BM1250 automatic analyzer (JEOL, Tokyo, Japan).